GlassScriptPhysician profile
Christopher Massad
NPI 1033640115
$668.02
in general payments reported to CMS, 2019-2025
13 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $272 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.64 | 2024-2025 | Lifevest |
| Siemens Medical Solutions USA, INC. | $130.45 | 2025 | Biograph Vision 600 (8 Ring/64 Ct) |
| Heartflow, INC. | $55.35 | 2025 | |
| Amgen INC. | $53.99 | 2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $44.08 | 2025 | |
| Inspire Medical Systems, INC. | $42.41 | 2024 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $37.05 | 2024-2025 | Camzyos, Eliquis |
| Pfizer INC. | $35.60 | 2025 | |
| Novo Nordisk INC | $34.75 | 2025 | Wegovy |
| Abbott Laboratories | $28.75 | 2024 | Cardiomems |
| Alnylam Pharmaceuticals INC. | $22.62 | 2024 | Amvuttra |
| Merck Sharp & Dohme LLC | $16.33 | 2024 | Verquvo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Massad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.